Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome

Last updated: May 9, 2025
Sponsor: Medical College of Wisconsin
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neurologic Disorders

Connective Tissue Diseases

Ulcers

Treatment

Acoustic vagal nerve stimulation (aVNS) treatment

Percutaneous vagal nerve stimulation (pVNS) device

Clinical Study ID

NCT05212129
1541191
  • Ages 10-18
  • All Genders

Study Summary

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). This study will address the clinical relationship between hEDS/Hypermobile Spectrum Disorders and autonomic regulation and see if there is a benefit of two forms of non-invasive vagal nerve stimulation therapies to reduce GI symptoms in hEDS and POTS. The study will also investigate plausible effects of these nerve stimulation therapies on gastric function and autonomic signaling.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Children aged 10-18 years old

  • Children with functional upper GI complaints and clinical suspicion for hEDS or HSDas well as a Beighton score of at least 4/9

  • Children with functional upper GI complaints and clinical suspicion for ANSdysfunction

  • De-identified data from our prior studies (IRB #689519 and IRB #1064187) of patientswith functional GI disorders who do NOT meet criteria for hEDS will be used as acomparison group

  • Children who are English-speaking and lack other explanation for symptoms

  • Children willing to participate and consent to this study (for children, have aparent willing to participate)

Exclusion

Exclusion Criteria:

A) Exclusion Criteria applying to all participants:

  • Medically complex children or those who take a medication or suffer from a diseasethat can explain symptoms will be excluded from participation in the study.

  • Adult subjects, children or their parents who have significant developmental delay (will be excluded due to difficulties in accurately completing the questionnairesand assessing symptoms)

  • Patients with findings of organic disease such as peptic ulcer disease, H.pylorigastritis, celiac disease, inflammatory bowel disease, allergic disorders, metabolicdisorder or any other chronic condition or medication that may cause chronic GIsymptoms will be excluded from the study.

  • Patients who are treated with a new drug affecting the central nervous system in thetwo weeks prior to enrollment will also be excluded.

  • Pregnancy (evaluating MD screens patients as they normally would during a clinicvisit (by questioning) and would only perform urine pregnancy test if clinicallyindicated (absence of menstrual period or other symptoms concerning for pregnancy)

  • Chronic alcohol/illicit drug use and/or smoking.

B) Exclusion Criteria for subjects undergoing pVNS therapy:

  • Severe dermatological condition or active infection of external or middle ear

  • Implanted electrical device

C) Exclusion Criteria for subjects undergoing aVNS therapy:

  • Hearing impaired

  • Sight impaired without correction

  • Seizure disorder

D) Exclusion Criteria for subjects undergoing gastric motor function sub-study:

  • Patients with pacemakers, metal clips used in previous surgery or other device whichare not compatible with MRI scanning

  • Claustrophobia or inability to lie still in the scanner

  • Orthodontic braces or permanent retainers

  • Patients who are unable to tolerate noise produced by the MRI

  • Egg allergy or anticipated inability to complete a standardized egg meal

E) Exclusion Criteria for subjects undergoing HepGI Biobank specimen collection sub-study:

  • Bleeding disorder for the specific biopsies

  • Recent antibiotic usage for fecal sample

  • Significant anemia or clinical status which will not allow safe blood draw requiredfor blood collection

  • Refusal of blood collection or to provide DNA sample

  • Inability or unwillingness on the individual (or parent/legal guardian) to provideclinical or family history.

Study Design

Total Participants: 90
Treatment Group(s): 2
Primary Treatment: Acoustic vagal nerve stimulation (aVNS) treatment
Phase:
Study Start date:
April 05, 2021
Estimated Completion Date:
December 31, 2026

Study Description

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS and Hypermobile Spectrum Disorders are associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). Symptoms are often disabling and associated with poor quality of life and high health care costs. The proposed research will address the following understudied areas: 1) the clinical relationship between hEDS and autonomic regulation, 2) the potential benefit of two forms of non-invasive vagal nerve stimulation (VNS) therapies in reducing functional GI symptoms in hEDS and POTS, and 3) plausible effects of these VNS therapies on gastric motor function and neurohormonal signaling.

Clinical reports document a high co-morbidity between autonomic disorders and hEDS. This prospective study will focus on three major clinical questions: 1) Are there reliable neurophysiological markers associated with hEDS that can provide insights into the 'neural mechanisms' resulting in multisystem co-morbidities? 2) Will innovative intervention techniques designed to enhance autonomic regulation via two non-invasive vagal nerve stimulation techniques (e.g., auricular and acoustic VNS) provide substantial symptom reduction and improve the hEDS patients' quality of life? 3) Can a novel gastric MRI technique capture gastric motor function abnormalities in adolescents with hEDS?

Connect with a study center

  • Medical College of Wisconsin

    Milwaukee, Wisconsin 53226
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.